DE69724098D1 - Chinolin- und benzimidazolderivate als bradykinin agonisten - Google Patents
Chinolin- und benzimidazolderivate als bradykinin agonistenInfo
- Publication number
- DE69724098D1 DE69724098D1 DE69724098T DE69724098T DE69724098D1 DE 69724098 D1 DE69724098 D1 DE 69724098D1 DE 69724098 T DE69724098 T DE 69724098T DE 69724098 T DE69724098 T DE 69724098T DE 69724098 D1 DE69724098 D1 DE 69724098D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- bradykinine
- chinoline
- agonists
- date aug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9602029.2A GB9602029D0 (en) | 1996-02-01 | 1996-02-01 | New heterocyclic compounds |
| GB9602029 | 1996-02-01 | ||
| PCT/JP1997/000233 WO1997028153A1 (en) | 1996-02-01 | 1997-01-31 | Chinoline and benzimidazole derivatives as bradykinin agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69724098D1 true DE69724098D1 (de) | 2003-09-18 |
| DE69724098T2 DE69724098T2 (de) | 2004-06-17 |
Family
ID=10787938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69724098T Expired - Lifetime DE69724098T2 (de) | 1996-02-01 | 1997-01-31 | Chinolin- und benzimidazolderivate als bradykinin agonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6015818A (de) |
| EP (1) | EP0879233B1 (de) |
| JP (1) | JP4092732B2 (de) |
| AT (1) | ATE247103T1 (de) |
| AU (1) | AU1556997A (de) |
| DE (1) | DE69724098T2 (de) |
| ES (1) | ES2202573T3 (de) |
| GB (1) | GB9602029D0 (de) |
| WO (1) | WO1997028153A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| JP2009530276A (ja) * | 2006-03-13 | 2009-08-27 | メルク エンド カムパニー インコーポレーテッド | ソマトスタチンアゴニスト |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| US8173668B1 (en) | 2007-06-05 | 2012-05-08 | Alcon Research, Ltd. | Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma |
| US7807629B1 (en) * | 2007-06-05 | 2010-10-05 | Alcon Research, Ltd. | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma |
| EP2420245A1 (de) * | 2010-08-18 | 2012-02-22 | Max-Delbrück-Centrum Für Molekulare Medizin | Therapeutische Verwendung von Bradykininrezeptor 1 oder 2 Agonisten oder Antagonisten, zur Modulierung von Kollateralblutgefäßwachstum |
| EP2568995B1 (de) | 2010-05-14 | 2016-07-20 | Max-Delbrück-Centrum für Molekulare Medizin | Therapeutische Verwendung von Bradykininrezeptor 1 Agonisten , zur Modulierung von Kollateralblutgefäßwachstum |
| TW201210584A (en) | 2010-08-18 | 2012-03-16 | Alcon Res Ltd | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma |
| EP2830643A1 (de) | 2012-03-26 | 2015-02-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Verfahren und pharmazeutische zusammensetzungen zur prävention oder behandlung eines ischämiebedingten organschadens |
| CN102977020A (zh) * | 2012-12-05 | 2013-03-20 | 四川大学 | 乌头碱型生物碱及其制备方法和以该化合物为强心和抗心衰活性成分的药物组合物及用途 |
| AU2018260628A1 (en) | 2017-04-25 | 2019-12-12 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
| TWI768156B (zh) | 2017-11-24 | 2022-06-21 | 荷蘭商帕法瑞斯荷蘭有限公司 | 新穎緩激肽ｂ２受體拮抗劑及其用途 |
| AR118983A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| AR118982A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| TW202320774A (zh) | 2021-08-05 | 2023-06-01 | 瑞士商帕法瑞斯有限責任公司 | 用於口服之舒緩肽ｂ２受體拮抗劑之基於脂質之組成物 |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
| WO2023180575A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574042A (en) * | 1992-11-02 | 1996-11-12 | Fujisawa Pharmaceutical Co., Ltd | Imidazo [1,2-a] pyridines and their pharmaceutical use |
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| AU2991595A (en) * | 1994-08-03 | 1996-03-04 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compound |
| DE19530032A1 (de) * | 1995-08-16 | 1997-02-20 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
1996
- 1996-02-01 GB GBGB9602029.2A patent/GB9602029D0/en active Pending
-
1997
- 1997-01-31 ES ES97901799T patent/ES2202573T3/es not_active Expired - Lifetime
- 1997-01-31 AT AT97901799T patent/ATE247103T1/de not_active IP Right Cessation
- 1997-01-31 US US09/117,453 patent/US6015818A/en not_active Expired - Lifetime
- 1997-01-31 DE DE69724098T patent/DE69724098T2/de not_active Expired - Lifetime
- 1997-01-31 AU AU15569/97A patent/AU1556997A/en not_active Abandoned
- 1997-01-31 JP JP52749397A patent/JP4092732B2/ja not_active Expired - Fee Related
- 1997-01-31 WO PCT/JP1997/000233 patent/WO1997028153A1/en active IP Right Grant
- 1997-01-31 EP EP97901799A patent/EP0879233B1/de not_active Expired - Lifetime
-
1999
- 1999-10-21 US US09/422,075 patent/US6127389A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0879233A1 (de) | 1998-11-25 |
| US6127389A (en) | 2000-10-03 |
| US6015818A (en) | 2000-01-18 |
| JP2001513749A (ja) | 2001-09-04 |
| WO1997028153A1 (en) | 1997-08-07 |
| ES2202573T3 (es) | 2004-04-01 |
| GB9602029D0 (en) | 1996-04-03 |
| EP0879233B1 (de) | 2003-08-13 |
| ATE247103T1 (de) | 2003-08-15 |
| AU1556997A (en) | 1997-08-22 |
| JP4092732B2 (ja) | 2008-05-28 |
| DE69724098T2 (de) | 2004-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69724098D1 (de) | Chinolin- und benzimidazolderivate als bradykinin agonisten | |
| MX9401408A (es) | Nuevos derivados heterociclicos. | |
| DE69633607D1 (de) | Piperidinderivate mit tachykinin-antagonistischer wirkung | |
| DE69428476T2 (de) | Heterocyclische Verbindungen als Bradykinin Antagonisten | |
| ATE269310T1 (de) | Pyridopyrimidinone, chinoline und anellierte n- heterozyklen als bradykinin-antagonisten | |
| WO1996016981A3 (en) | Peptide compounds for prevention and/or treatment of no-mediated diseases | |
| ATE219765T1 (de) | Indolderivate als cgmp-pde inhibitoren | |
| ATE273958T1 (de) | Heterocyclische verbindungen als h+-atpasen | |
| ATE152719T1 (de) | Chinolylbenzofuran derivate als leukotrien- antagonisten | |
| ES2147836T3 (es) | Derivados de 4,5-diariloxazol. | |
| DK0783501T3 (da) | Pyrimidonderivater med anti-fungal aktivitet | |
| ES8404990A1 (es) | Un procedimiento para la preparacion de derivados de prolina. | |
| ATE254121T1 (de) | Heterocyclische verbindungen als bradykinin antagonisten | |
| BR0108816A (pt) | Derivados de quinolina como antagonistas alfa-2 | |
| BR0015195A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas | |
| ATE234818T1 (de) | Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| ATE184593T1 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
| TW350838B (en) | Quinoline derivatives | |
| NZ336969A (en) | Substituted 4-aminoalkoxy-1H-benzimidazole derivatives useful as dopamine autoreceptor (D2) agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP |